Moteur de recherche d’entreprises européennes
Financement de l’UE (8 547 712 €) : Prédiction et manipulation de la réponse immunitaire basée sur les tumeurs multiples Hor01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Prédiction et manipulation de la réponse immunitaire basée sur les tumeurs multiples
Only few patients respond to tumor treatment as desired. Treatment heavily relies on host tumor interactions, including exploiting the host immune response against the tumor. The underlying mechanisms of host tumor interaction are largely unknown, guidance on specific intervention is missing. To improve outcome, better understanding of tumor-host interaction is needed. Large numbers of molecular snapshots will provide increased phenotyping coverage and better represent tumor-host evolution over time. In an innovative approach, MULTIR aims at investigating not a single tumor entity, but at compiling data from melanoma, lung and bladder cancer (most drugs target specific molecular features, irrespective of the tumor origin) to identify with high power the critical elements in the tumor-host interaction responsible for therapy response. In a multi-disciplinary approach involving leading clinicians, immunologists, experts in omics, digital technologies, social sciences and patient representatives from 10 EU countries and beyond, and an extensive outreach plan to ensure rapid transfer of MULTIR output to society, MULTIR combines existing multi-layer (epidemiological, genetic, clinical, pathologic, imaging, molecular) data from major studies on these tumors, using AI-based approaches to unveil functional modules regulating tumor-host interactions followed by validation of findings in models and synthetic patients. Harmonization with major EU initiatives will maximize use of European resources. Impact on all scientific, technological and societal levels is expected, including increased understanding of tumor-host interactions, generation of a unique resource of harmonized data on three major cancer types available to the community in compliance to the legal and ethics framework, boost of drug discovery, and an AI-based predictor for treatment response. MULTIR outreach plan includes policymakers and regulators, to support prompt assessment and uptake into the health systems. This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)”.
| Royal Institution FOR THE Advancement OF Learning Mcgill University | ? |
| Aarhus Universitet | 1 498 228 € |
| ATOMIC INTELLIGENCE d.o.o. | 815 750 € |
| Centre Hospitalier Universitaire de Nantes | 300 838 € |
| Elliniki Ogkologiki Erevnitiki Omada | 687 500 € |
| Eticas Data Society | 322 500 € |
| Exelixis Diacheirisi Erevnas Kai Epikoinonia ΕΕ | 277 500 € |
| Folkehelseinstituttet | 211 625 € |
| Idryma Iatroviologikon Ereunon Akademias Athinon | 315 280 € |
| Institut National de la Sante et de la Recherche Medicale | 851 535 € |
| Medizinische Universitaet Wien | 254 750 € |
| MOSAIQUES DIAGNOSTICS GmbH | 736 703 € |
| Sorbonne Universite | 50 000 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 477 125 € |
| UNIVERSITAETSKLINIKUM ESSEN | 807 375 € |
| University College Dublin, National University of Ireland, Dublin | 941 004 € |
https://cordis.europa.eu/project/id/101136926
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Royal Institution FOR THE Advancement OF Learning Mcgill University, Montreal, Canada.
